These estimates are not a guarantee
These projections are based on clinical validation data from DERM, Skin Analytics’ CE-marked AI medical device. Actual results may vary depending on local referral patterns, case mix, and implementation specifics. This model assumes ~30% of mole check referrals can be triaged as benign — figures are indicative and should not be treated as guaranteed outcomes.